The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy
Open accessAbstract
Angiogenesis in normal and pathological conditions is a multi-step process governed by positive and negative endogenous regulators. Many growth factors are involved in different steps of angiogenesis, like vascular endothelial growth factors (VEGF), fibroblast growth factor (FGF)-2 or platelet-derived growth factors (PDGF). From these, VEGF and FGF-2 were extensively investigated and it was shown that they significantly contribute to the induction and progression of angiogenesis. A lot of evidence has been accumulated in last 10 years that supports the contribution of PDGF/PDGFR axis in developing angiogenesis in both normal and tumoral conditions. The crucial role of PDGF-B and PDGFR-β in angiogenesis has been demonstrated by gene targeting experiments, and their expression correlates with increased vascularity and maturation of the vascular wall. PDGF and their receptors were identified in a large variety of human tumor cells. In experimental models it was shown that inhibition of PDGF reduces interstitial fluid pressure in tumors and enhances the effect of chemotherapy. PDGFR have been involved in the cardiovascular development and their loss leads to a disruption in yolk sac blood vessels development. PDGFRβ expression by pericytes is necessary for their recruitment and integration in the wall of tumor vessels. Endothelial cells of tumor-associated blood vessels can express PDGFR. Based on these data, it was suggested the potential benefit of targeting PDGFR in the treatment of solid tumors. The molecular mechanisms of PDGF/PDGFR-mediated angiogenesis are not fully understood, but it was shown that tyrosine kinase inhibitors reduce tumor growth and angiogenesis in experimental xenograft models, and recent data demonstrated their efficacy in chemoresistant tumors. The in vivo effects of PDGFR inhibitors are more complex, based on the cross-talk with other angiogenic factors. In this review, we summarize data regarding the mechanisms and significance of PDGF/PDGFR expression in normal conditions and tumors, focusing on this axis as a potential target for antitumor and antiangiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Ross, R., Glomset, J., Kariya, B., & Harker, L. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1207 · Cited by 1,847
Hellström, M., Kalén, M., Lindahl, P., Abramsson, A., & Betsholtz, C. (1999) · Development · doi:10.1242/dev.126.14.3047 · Cited by 1,700
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Malignant glioma: genetics and biology of a grave matter
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001) · Genes & Development · doi:10.1101/gad.891601 · Cited by 1,229
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities.
Levéen, P., Pekny, M., Gebre-Medhin, S., Swolin, B., Larsson, E., & Betsholtz, C. (1994) · Genes & Development · doi:10.1101/gad.8.16.1875 · Cited by 1,131
Role of vascular endothelial growth factor in regulation of physiological angiogenesis
Ferrara, N. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1358 · Cited by 1,085
Endothelial-pericyte interactions in angiogenesis
Gerhardt, H., & Betsholtz, C. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0745-x · Cited by 1,057
Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.
Soriano, P. (1994) · Genes & Development · doi:10.1101/gad.8.16.1888 · Cited by 989
The PDGF family: four gene products form five dimeric isoforms
Fredriksson, L., Li, H., & Eriksson, U. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.007 · Cited by 838
Cao, R., Bråkenhielm, E., Pawliuk, R., Wariaro, D., Post, M. J., Wahlberg, E., Leboulch, P., & Cao, Y. (2003) · Nature Medicine · doi:10.1038/nm848 · Cited by 721
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Platelets as a source of fibroblast growth-promoting activity
Kohler, N., & Lipton, A. (1974) · Experimental Cell Research · doi:10.1016/0014-4827(74)90484-4 · Cited by 626
PDGF-C is a new protease-activated ligand for the PDGF α-receptor
Li, X., Pontén, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., Bäckström, G., Hellström, M., Boström, H., Li, H., et al. (2000) · Nature Cell Biology · doi:10.1038/35010579 · Cited by 623
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor
Bergsten, E., Uutela, M., Li, X., Pietras, K., Östman, A., Heldin, C.-H., Alitalo, K., & Eriksson, U. (2001) · Nature Cell Biology · doi:10.1038/35074588 · Cited by 562
Abramsson, A., Lindblom, P., & Betsholtz, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18549 · Cited by 562
PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis
Cao, R., Björndahl, M. A., Religa, P., Clasper, S., Garvin, S., Galter, D., Meister, B., Ikomi, F., Tritsaris, K., Dissing, S., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.034 · Cited by 527
Pericytes and vascular stability
VONTELL, D., ARMULIK, A., & BETSHOLTZ, C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.019 · Cited by 502
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors.
Battegay, E. J., Rupp, J., Iruela-Arispe, L., Sage, E. H., & Pech, M. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.4.917 · Cited by 455
Pietras, K., Pahler, J., Bergers, G., & Hanahan, D. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050019 · Cited by 453
Insight into the physiological functions of PDGF through genetic studies in mice
Betsholtz, C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.005 · Cited by 437
Platelet-derived growth factor: purification and partial characterization.
Heldin, C. H., Westermark, B., & Wasteson, A. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.8.3722 · Cited by 429
Lokker, N. A., Sullivan, C. M., Hollenbach, S. J., Israel, M. A., & Giese, N. A. (2002) · PubMed · Cited by 429
Guo, P., Hu, B., Gu, W., Xu, L., Wang, D., Huang, H.-J. S., Cavenee, W. K., & Cheng, S.-Y. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63905-3 · Cited by 367
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
Östman, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.002 · Cited by 326
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Dong, J., Grunstein, J., Tejada, M., Peale, F., Frantz, G., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 295
Nissen, L. J., Cao, R., Hedlund, E.-M., Wang, Z., Zhao, X., Wetterskog, D., Funa, K., Bråkenhielm, E., & Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32479 · Cited by 290
Uehara, H., Kim, S. J., Karashima, T., Shepherd, D. L., Fan, D., Tsan, R., Killion, J. J., Logothetis, C., Mathew, P., & Fidler, I. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.458 · Cited by 280
Kano, M. R., Morishita, Y., Iwata, C., Iwasaka, S., Watabe, T., Ouchi, Y., Miyazono, K., & Miyazawa, K. (2005) · Journal of Cell Science · doi:10.1242/jcs.02483 · Cited by 277
Wyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., Byrnes, C., Sanders, K., & Sosman, J. A. (2006) · Cancer · doi:10.1002/cncr.21834 · Cited by 274
A platelet factor stimulating human normal glial cells
WESTERMARK, B., & WASTESON, P. (1976) · Experimental Cell Research · doi:10.1016/0014-4827(76)90476-6 · Cited by 265
Ek, B., & Heldin, C. H. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34044-4 · Cited by 248
Takahashi, Y., Bucana, C. D., Liu, W., Yoneda, J., Kitadai, Y., Cleary, K. R., & Ellis, L. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.16.1146 · Cited by 239
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
Murukesh, N., Dive, C., & Jayson, G. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605483 · Cited by 237
Cao, R., Bråkenhielm, E., Li, X., Pietras, K., Widenfalk, J., Östman, A., Eriksson, U., & Cao, Y. (2002) · The FASEB Journal · doi:10.1096/fj.02-0319com · Cited by 229
Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis
Shih, A. H., Dai, C., Hu, X., Rosenblum, M. K., Koutcher, J. A., & Holland, E. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3831 · Cited by 222
New Members of the Platelet-Derived Growth Factor Family of Mitogens
Heldin, C.-H., Eriksson, U., & Östman, A. (2002) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2707 · Cited by 221
Henriksen, R., Funa, K., Wilander, E., Bäckström, T., Ridderheim, M., & Öberg, K. (1993) · PubMed · Cited by 219
Platelet-derived growth factor (PDGF) and glial tumorigenesis
Shih, A. H., & Holland, E. C. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.02.002 · Cited by 214
Phase II trial of imatinib mesylate in patients with metastatic melanoma
Kim, K. B., Eton, O., Davis, D. W., Frazier, M. L., McConkey, D. J., Diwan, A. H., Papadopoulos, N. E., Bedikian, A. Y., Camacho, L. H., Ross, M. I., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604482 · Cited by 213
Carvalho, I., Milanezi, F., Martins, A., Reis, R. M., & Schmitt, F. (2005) · Breast Cancer Research · doi:10.1186/bcr1304 · Cited by 206
Plate, K. H., Breier, G., Farrell, C. L., et al. (1992) · PubMed · Cited by 204
Furuhashi, M., Sjöblom, T., Abramsson, A., Ellingsen, J., Micke, P., Li, H., Bergsten-Folestad, E., Eriksson, U., Heuchel, R., Betsholtz, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1489 · Cited by 203
Endogenous inhibitors of angiogenesis
Ribatti, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.019 · Cited by 191
Fujimoto, K., Hosotani, R., Wada, M., Lee, J.-U., Koshiba, T., Miyamoto, Y., Tsuji, S., Nakajima, S., Doi, R., & Imamura, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00069-0 · Cited by 168
Laschke, M. W., Elitzsch, A., Vollmar, B., Vajkoczy, P., & Menger, M. D. (2006) · Human Reproduction · doi:10.1093/humrep/dei308 · Cited by 168
Chott, A., Sun, Z., Morganstern, D., Pan, J., Li, T., Susani, M., Mosberger, I., Upton, M. P., Bubley, G. J., & Balk, S. P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65229-7 · Cited by 161
Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
R BOARD, & Jayson, G. C. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.03.004 · Cited by 157
Beppu, K., Jaboine, J., Merchant, M., Mackall, C. L., & Thiele, C. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh004 · Cited by 149
Timke, C., Zieher, H., Roth, A. K., Hauser, K., Lipson, K. E., Weber, K. J., Debus, J., Abdollahi, A., & Huber, P. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1893 · Cited by 137
Tejada, M. L., Yu, L., Dong, J., Jung, K., Meng, G., Peale, F. V., Jr., Frantz, G. D., Hall, L., Liang, X., Gerber, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1770 · Cited by 137
Uutela, M., Laurén, J., Bergsten, E., Li, X., Horelli‐Kuitunen, N., Eriksson, U., & Alitalo, K. K. (2001) · Circulation · doi:10.1161/01.cir.103.18.2242 · Cited by 134
Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451
Roberts, W. G., Whalen, P. M., Söderström, E., Moraski, G. C., Lyssikatos, J. P., Wang, H. F., Cooper, B. A., Baker, D. A., Savage, D. M., Dalvie, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.957.65.3 · Cited by 132
Mathew, P. F., Thall, P. F., JONES, D. M., Perez, C. A., Bucana, C. D., Troncoso, P., Kim, S.-J., Fidler, I. J., & Logothetis, C. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.116 · Cited by 125
Coltrera, M. D., Wang, J., Porter, P. L., & Gown, A. M. (1995) · PubMed · Cited by 121
Antoniades, H. N., Galanopoulos, T., Neville-Golden, J., & O’Hara, C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3942 · Cited by 120
Dønnem, T., Al‐Saad, S., Al-Shibli, K. I., Andersen, S., Busund, L., & Bremnes, R. M. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181834f52 · Cited by 116
di Tomaso, E., London, N. R., Fuja, D. G., Logie, J. J., Tyrrell, J. A., Kamoun, W. S., Munn, L. L., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005123 · Cited by 116
Kubo, T., Piperdi, S., Rosenblum, J., Antonescu, C. R., Chen, W., Kim, H., Huvos, A. G., Sowers, R. S., Meyers, P. A., Healey, J. H., et al. (2008) · Cancer · doi:10.1002/cncr.23437 · Cited by 112
Schilder, R. J., Sill, M. W., Lee, R. B., Shaw, T. J., Senterman, M. K., Klein–Szanto, A. J., Miner, Z., & Vanderhyden, B. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3420 · Cited by 110
Biology of platelet‐derived growth factors in development
Betsholtz, C. (2003) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.10030 · Cited by 107
Liang, Y., Robinson, D. F., Dennig, J., Suske, G., & Fahl, W. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.11792 · Cited by 106
Seymour, L., Dajee, D., & Bezwoda, W. R. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665802 · Cited by 102
Lange, S., Heger, J., Euler, G., Wartenberg, M., Piper, H. M., & Sauer, H. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn258 · Cited by 102
Coluccia, A. M. L., Cirulli, T., Neri, P. E., Mangieri, D., Colanardi, M. C., Gnoni, A., Renzo, N. D., Dammacco, F., Tassone, P., Ribatti, D., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116590 · Cited by 101
Kuhnert, F., Tam, B. Y. Y., Sennino, B., Gray, J. T., Yuan, J., Jocson, A., Nayak, N. R., Mulligan, R. C., McDonald, D. M., & Kuo, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803194105 · Cited by 98
Kim, S.-J., Uehara, H., Yazıcı, S., Busby, J. E., Nakamura, T., He, J., Maya, M., Logothetis, C. J., Mathew, P. F., Wang, X., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj211 · Cited by 94
Cristofanilli, M., Morandi, P., Krishnamurthy, S., Reuben, J. M., Lee, B.-N., Francis, D., Booser, D. J., Green, M. C., Arun, B., Pusztai, L., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn352 · Cited by 93
Kontovinis, L., Papazisis, K. T., Touplikioti, P., Andreadis, C. B., Mouratidou, D., & Kortsaris, A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-82 · Cited by 88
Platelet-derived growth factor receptor-β promotes early endothelial cell differentiation
Rolny, C., Nilsson, I., Magnusson, P. U., Armulik, A., Jakobsson, L., Wentzel, P., Lindblom, P., Norlin, J., Betsholtz, C., Heuchel, R. L., et al. (2006) · Blood · doi:10.1182/blood-2006-04-014894 · Cited by 87
Khachigian, L. M., Fries, J., Benz, M. W., Bonthron, D. T., & Collins, T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31695-2 · Cited by 85
Role of Platelet-Derived Growth Factors in Angiogenesis and Alveogenesis
Lindahl, P., Boström, H., Karlsson, L., Hellström, M., Kalén, M., & Betsholtz, C. (1999) · Current topics in pathology · doi:10.1007/978-3-642-58456-5_4 · Cited by 85
Dønnem, T., Al‐Saad, S., Al-Shibli, K. I., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp296 · Cited by 80
Magnusson, P. U., Looman, C., Åhgren, A., Wu, Y. L., Claesson, L., & Heuchel, R. L. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000282198.60701.94 · Cited by 79
PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer
Nakamura, Y., Tanaka, F., Yoshikawa, Y., Mimori, K., Inoue, H., Yanaga, K. K., & Mori, M. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9943-9 · Cited by 71
Tsutsumi, N., Yonemitsu, Y., Shikada, Y., Onimaru, M., Tanii, M., Okano, S., Kaneko, K., Hasegawa, M., Hashizume, M., Maehara, Y., et al. (2004) · Circulation Research · doi:10.1161/01.res.0000126925.66005.39 · Cited by 66
Lederle, W., Stark, H., Skobe, M., Fusenig, N. E., & Mueller, M. M. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060120 · Cited by 64
Crosslinking heparin to collagen scaffolds for the delivery of human platelet‐derived growth factor
Sun, B., Chen, B., Zhao, Y., Sun, W., Chen, K., Zhang, J., Wei, Z., Xiao, Z., & Dai, J. (2009) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31411 · Cited by 60
Marchis, F. D., Ribatti, D., Giampietri, C., et al. (2002) · Blood · doi:10.1182/blood.v99.6.2045 · Cited by 59
Design of growth factor antagonists with antiangiogenic and antitumor properties
Sebti, S. M., & Hamilton, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1204121 · Cited by 58
Lamy, S., Beaulieu, É., Labbé, D. P., Bédard, V., Moghrabi, A., Barrette, S., Gingras, D., & Béliveau, R. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn070 · Cited by 58
Sennino, B., Kuhnert, F., Tabruyn, S. P., Mancuso, M. R., Hu‐Lowe, D. D., Kuo, C. J., & McDonald, D. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3779 · Cited by 57
Eckel, F., von Delius, S., Mayr, M. F., Dobritz, M., Fend, F., Hosius, C., Schleyer, E., Schulte‐Frohlinde, E., Schmid, R. M., & Lersch, C. (2005) · Oncology · doi:10.1159/000089990 · Cited by 56
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma
Longatto‐Filho, A., Pinheiro, C. M., Martinho, O., Moreira, M. A., Jubé, L. F., Queiroz, G. S., Schmitt, F. C., Baltazar, F., & Reis, R. M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-212 · Cited by 56
Servidei, T., Riccardi, A., Sanguinetti, M., Dominici, C., & Riccardi, R. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20659 · Cited by 52
Chung, C. K., & Antoniades, H. N. (1992) · PubMed · Cited by 49
Double target for tumor mass destruction
Saharinen, P., & Alitalo, K. K. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18539 · Cited by 48
French, W. J., Creemers, E. E., & Tallquist, M. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00441-08 · Cited by 44
Histological expression of angiogenic factors: VEGF, PDGFRα, and HIF-1α in Hodgkin lymphoma
Passam, F. H., Alexandrakis, M. G., Kafousi, M., Fotinou, M., Darivianaki, K., Tsirakis, G., Roussou, P. A., Stathopoulos, E. N., & Siafakas, N. M. (2008) · Pathology - Research and Practice · doi:10.1016/j.prp.2008.07.007 · Cited by 41
Campbell, J. S., Johnson, M. M., Bauer, R. L., Hudkins, K. L., Gilbertson, D. G., Riehle, K. J., Yeh, M. M., Alpers, C. E., & Fausto, N. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00235.x · Cited by 41
Shen, J., Vil, M. D., Zhang, H., Tonra, J. R., Rong, L., Damoci, C., Prewett, M. C., Deevi, D. S., Kearney, J. A., Surguladze, D., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.075 · Cited by 40
Seki, N., Kodama, J., Hongo, A., Miyagi, Y., Yoshinouchi, M., & Kudo, T. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00201-4 · Cited by 39
Platelet-Derived Growth Factor-Receptor α Strongly Inhibits Melanoma Growth In Vitro and In Vivo
Faraone, D., Aguzzi, M. S., Toietta, G., Facchiano, A. M., Facchiano, F., Magenta, A., Martelli, F., Truffa, S., Cesareo, E., Ribatti, D., et al. (2009) · Neoplasia · doi:10.1593/neo.09408 · Cited by 37
Krasagakis, K., Garbe, C., & Orfanos, C. E. (1993) · PubMed · Cited by 30
Krasagakis, K., Garbe, C., & Orfanos, C. E. (1993) · Melanoma Research · doi:10.1097/00008390-199311000-00005 · Cited by 29
Vrekoussis, T., Stathopoulos, E., Kafousi, M., Navrozoglou, I., & Zoras, O. (2007) · Oncology Reports · doi:10.3892/or.17.5.1115 · Cited by 26
Ghanem, M. A., Nijman, R. J. M., Safan, M. A., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09211.x · Cited by 18
Werth, C., Stuhlmann, D., Cat, B., Steinbrenner, H., Alili, L., Sies, H., & Brenneisen, P. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm296 · Cited by 16
Li, W.-L., Yamada, Y., Ueno, M., et al. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj151 · Cited by 14
Synectin‐dependent regulation of arterial maturation
Paye, J. M. D., Phng, L., Lanahan, A. A., Gerhard, H., & Simons, M. (2009) · Developmental Dynamics · doi:10.1002/dvdy.21880 · Cited by 13
Platelet-Derived Growth Factor Pathway Inhibitors in Ovarian Cancer
Schmitt, J., & Matei, D. E. (2008) · Clinical Ovarian Cancer · doi:10.3816/coc.2008.n.013 · Cited by 10
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Brain Pericytes As Mediators of Neuroinflammation
Rustenhoven, J., Jansson, D., Smyth, L. C., & Dragunow, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.001 · Cited by 371
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Pathophysiological implications of hypoxia in human diseases
Chen, P.-S., Chiu, W.-T., Hsu, P.-L., Lin, S.-C., Peng, I.-C., Wang, C.-Y., & Tsai, S.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00658-7 · Cited by 318
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 283
Metadata
- Authors
- Raica, M., & Cimpean, A. M.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2010-03-11
- Volume
- 3
- Issue
- 3
- Pages
- 572-599
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2093555412
- Cited by
- 304
- References
- 108
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.